Subdural Hematoma
25
8
8
8
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.0%
2 terminated out of 25 trials
80.0%
-6.6% vs benchmark
16%
4 trials in Phase 3/4
38%
3 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 8 completed trials
Clinical Trials (25)
MMA Embolization With NeoCast for Subacute and Chronic Subdural Hematoma
Al Prediction of Sarcopenia Risk in Neurocritical ICU Patients
Outcomes of Traumatic Intracranial Hemorrhage in the Elderly
Non-Thermal Plasma to Reduce Recurrence in Chronic Subdural Hematoma
The Use of Tranexamic Acid in the Treatment of Symptomatic Subdural Hematoma
Study On Histoacryl Used For Embolization Of Middle Meningeal Artery (MMA) In Chronic Subdural Hematoma (CSDH) (HARMONY)
Neurosurgical Outcome Network
Embolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)
Embolization of the Middle Meningeal Artery With ONYX™ Liquid Embolic System for Subacute and Chronic Subdural Hematoma
Scalp Block Versus General Anesthesia in Patients Undergoing Evacuation of Subdural Hematoma Via Burr Hole
Comparison of Narcotrend and Cerebral Function Analysing Monitor in Intensive Care to Monitor Seizures and Deep Sedation
AFFECT Study for Patients With Intraventricular Hemorrhage, Subarachnoid Hemorrhage, Subdural Hematoma, and Ventriculitis
Anticoagulation Therapy Timing in Atrial Fibrillation After Acute and Chronic Subdural Hematoma
Dartmouth Middle Meningeal Embolization Trial (DaMMET)
Prospective Study on the Use of Middle Meningeal Artery Embolization for Chronic Subdural Haematoma
Evaluation of One Burr Hole Evacuation for Subdural Hematoma
Augmented Reality for Subdural Drain Placement
Patient Registry for Patients With Chronic Subdural Hematoma
Start or STop Anticoagulants Randomised Trial (SoSTART)
A Study on the Safety of Tranexamic Acid for the Chronic Subdural Hematoma Population